Pharma & Biotech

Bayer's latest financial results present a stark dichotomy. While the company's core business operations demonstrate resilience, its bottom line continues...

ImmunityBio's impressive full-year 2025 results were met with a severe sell-off, highlighting the persistent volatility that continues to characterize this...

Investor focus returns to Viking Therapeutics next week as company executives prepare to outline their strategic vision at two major...

While demand for weight-loss medications remains robust, inconsistent insurance coverage continues to be a significant barrier for many patients. Pharmaceutical...

Despite securing two significant regulatory approvals from the U.S. Food and Drug Administration (FDA) in early March 2026, shares of...

The pharmaceutical giant AbbVie is finding an unexpected growth opportunity in the surge of popularity for weight-loss drugs. While medications...

Axsome Therapeutics is making a bold and resource-intensive move to significantly expand its commercial operations. The biopharmaceutical company has announced...

The clinical-stage biotech firm Replimune is advancing its lead therapeutic candidate with a clear emphasis on navigating regulatory requirements. The...

The equity of German biotechnology firm BioNTech is navigating a period of significant volatility. As the company accelerates its strategic...

The future value of contingent value rights (CVRs) issued following AbbVie's acquisition of Landos Biopharma hinges on a single, upcoming...